

8 April 2024

**Intuitive Investments Group plc
("IIG" or the "Company")**

Issue and Allotment of Ordinary Shares

Intuitive Investments Group plc (SFS: IIG), the closed-end investment company focussed on fast growing and high potential opportunities in the Technology, Life Sciences and Healthcare sectors, announces the issue and allotment of 159,642 ordinary shares of 10 pence each ("**Ordinary Shares**"), fully paid. These shares were issued for cash at a price of £1.566 per share to raise £250,000 for the Company.

Application has been made for the new Ordinary Shares, which will rank equally with the existing Ordinary Shares of the Company, to be admitted to trading on Specialist Fund Segment of the Main Market, becoming effective in accordance with the admission and disclosure standards of the London Stock Exchange. It is expected that admission will become effective and dealings in the new Ordinary Shares will commence at 8:00 a.m. on or around 9 April 2024 ("**Admission**").

Following Admission, the Company's issued share capital will consist of 202,293,166 Ordinary Shares. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company will be 202,293,166. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Intuitive Investments Group plc	www.iigplc.com
Sir Nigel Rudd, Non-Executive Chairman Robert Naylor, CEO Giles Willits, CIO	Via FTI Consulting
Cavendish Capital Markets Limited James King / William Talkington / Daniel Balabanoff	+44 (0) 20 7397 8900
SP Angel Corporate Finance LLP - Financial Adviser Jeff Keating / David Hignell / Kasia Brzozowska	+44 (0) 20 3470 0470
FTI Consulting Jamie Ricketts / Valerija Cymbal / Jemima Gurney	+44 (0) 20 3727 1000 IIG@fticonsulting.com

About Intuitive Investments Group plc

IIG is an investment company seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences and Technology businesses operating predominantly in the UK, continental Europe, the US and APAC, utilising the Board's experience to seek to generate capital growth over the long term for shareholders.